N
NRx Pharmaceuticals, Inc. (NRXP)
NCM – Real vaqt narxi. Valyuta: USD
3.36
-0.04 (-1.18%)
Yopilishda: Aug 12, 2026, 4:00 PM EDT
3.40
+0.04 (1.18%)
Bozordan keyin: Aug 12, 2026, 6:41 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
3.36
-0.04 (-1.18%)
Yopilishda: Aug 12, 2026, 4:00 PM EDT
3.40
+0.04 (1.18%)
Bozordan keyin: Aug 12, 2026, 6:41 PM EDT
NRx Pharmaceuticals, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda o'z joniga qasd qilish depressiyasi, post-travmatik stress buzilishi (PTSS) va shizofreniyani o'z ichiga olgan markaziy asab tizimi buzilishlarini davolash uchun terapevtik vositalarni ishlab chiqadi. U NRx va Dura segmentlari orqali ishlaydi. Kompaniya bipolyar depressiya va subakut ideatsiya va xatti-harakatlar uchun 2/3 bosqichli klinik sinovlarda bo'lgan D-tsikloserin (DCS) va lurasidonning og'iz orqali qabul qilinadigan qattiq dozali kombinatsiyasi bo'lgan NRX-101; o'z joniga qasd qilish depressiyasini davolash uchun tomir ichiga yuborish uchun ketaminning konservantsiz formulasi bo'lgan NRX-100; va ketaminning jenerik konservantsiz formulasi bo'lgan KETAFREEni ishlab chiqadi. U, shuningdek, davolashga chidamli depressiya va PTSSga chalingan bemorlarga neyroplastik dorilar, transkranial magnit stimulyatsiya (TMS), raqamli terapevtik vositalar va giperbarik terapiya; ketamin infuzion terapiyasi; stellat ganglion bloklari; Spravato yuborish; psixoterapiya; va dori-darmonlarni boshqarish kombinatsiyasidan foydalangan holda aniqlikka asoslangan intervensiya psixiatriya xizmatlarini taqdim etadi. Kompaniya Glytech LLC bilan ishlab chiqish va litsenziyalash shartnomasiga ega. NRx Pharmaceuticals, Inc. 2015-yilda tashkil etilgan va shtab-kvartirasi Vaylmington, Delaverda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dennis K. McBride Ph.D. | Chief Strategy Officer & Director |
| Dr. Hervé Perron HDR, Ph.D. | Chief Scientist |
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chairman & CEO |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer |
| Mr. Joseph M. Casper | Chief Operating Officer |
| Mr. Michael Taylor | Chief Development Officer & Director |
| Mr. Michael S. Abrams M.B.A. | CFO & Treasurer |
| Prof. Joshua C. Brown M.D., Ph.D. | Chief Medical Innovation Officer |
| Suzanne Messere | Investor Relations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-07 | 8-K | nrxp20260806_8k.htm |
| 2026-07-22 | 8-K | nrxp20260722_8k.htm |
| 2026-06-04 | 8-K | nrxp20260603_8k.htm |
| 2026-06-02 | 8-K | nrxp20260602_8k.htm |
| 2026-05-15 | 10-Q | nrxp20260331_10q.htm |
| 2026-03-24 | 8-K | nrxp20260324_8k.htm |
| 2026-03-23 | 10-K | nrxp20251231_10k.htm |
| 2026-02-24 | DEFA14A | nrxp20260224_defa14a.htm |
| 2026-02-23 | DEF 14A | nrxp20260218_def14a.htm |
| 2026-02-23 | ARS | nrxars.pdf |